Table 1.
Category of Evidence/Strength of Recommendation Rating Scale
| Therapy | Category of Evidence | Strength of Recommendation |
|---|---|---|
| 1st Line | ||
| Clindamycin (topical) 1 | IIb | Possible B |
| Clindamycin/Rifampicin (oral) 2 | III | C |
| Adalimumab (subcutaneous) 3 | Ib | A |
| Tetracycline (oral) | IIb | B |
| Surgery | ||
| Excision or Curettage of Individual Lesions | III | C |
| Total Excision of the Lesions and Surrounding Hair-Bearing Skin | IIb | B |
| Second Intention Healing | IIb | B |
| Primary Closure | III | C |
| Reconstruction with Skin Grafting & NPWT | III | C |
| Reconstruction with Flap Plasty | Ia/IIa | A/B |
| Deroofing | IV | D |
| Carbon Dioxide Laser Therapy | Ib | A |
| Nd:YAG Laser | Ib | A |
| IPL | IV | D |
| 2nd Line | ||
| Zinc Gluconate | III | C |
| Resorcinol | III | C |
| Intralesional Corticosteroids | IV | D |
| Systemic Corticosteroids | IV | D |
| Infliximab | Ib/IIa | B |
| Acitretin/Etretinate | III | C |
| 3rd Line | ||
| Colchicine | IV | D |
| Botulinum Toxin | IV | D |
| Isotretinoin | IV | D |
| Dapsone | IV | D |
| Cyclosporine | IV | D |
| Hormones | IV | D |
| Pain Control | ||
| NSAIDS | IV | D |
| Opiates | IV | D |
| Dressings | ||
| No studies have been published to date on the use of specific dressing or wound care methodology in HS. Choice of dressing is based on clinical experience. | IV | D |
1. Single double-blind, placebo-controlled, randomized trial. Hurley stage 1–2.
2. Evaluated in case series.
3. Multiple prospective randomized, double-blind, placebo-controlled trials (Pioneer 1 and 2).